戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  FLJ22028 (overexpressed in all GCTs, except choriocarcinomas).
2 y included yolk sac, embryonal carcinoma, or choriocarcinoma.
3 lastic cell line, Rcho-1, derived from a rat choriocarcinoma.
4 e tissues, particularly in complete mole and choriocarcinoma.
5  inhibition may be a strategy to treat MTX-R choriocarcinoma.
6 urine of pregnant women and of patients with choriocarcinoma.
7 ma, embryonal carcinoma, yolk sac tumor, and choriocarcinoma.
8 ising and repeat uterine evacuation revealed choriocarcinoma.
9 lateral non-gestational pure primary ovarian choriocarcinoma.
10 Our results show that PMs can transform into choriocarcinoma.
11 es, teratoma (TE), yolk sac tumor (YST), and choriocarcinoma.
12  partial mole, complete mole and gestational choriocarcinoma.
13 al autocrine mechanism in the development of choriocarcinomas.
14 e investigate whether PMs can transform into choriocarcinomas.
15 sclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma, and 1% teratoma.
16 rocess may contribute to the pathogenesis of choriocarcinoma, a highly invasive and lethal form of ca
17 ients with no metastatic disease and without choriocarcinoma, a pretreatment human chorionic gonadotr
18 hereas in patients with either metastases or choriocarcinoma, a pretreatment human chorionic gonadotr
19  as an essential angiogenic growth factor in choriocarcinoma and melanoma, promoting metastatic growt
20 pports the highly aggressive growth of human choriocarcinoma and possibly of the human trophoblast.
21 ally reduced in both IFN-gamma-treated human choriocarcinoma and primary TBCs compared with HeLa cell
22 re expressed in malignant trophoblasts (i.e. choriocarcinoma) and in the proliferative and in the inv
23 truma ovarii, thyrotropin-secreting tumours, choriocarcinoma, and amiodarone-induced thyrotoxicosis a
24 nd the malignant disorders of invasive mole, choriocarcinoma, and the rare placental-site trophoblast
25 diameter, one patient had a large metastatic choriocarcinoma; and three patients had low-grade astroc
26                                              Choriocarcinomas are embryonal tumours with loss of impr
27                                              Choriocarcinoma arising de novo from the ovary is very r
28                     To determine whether the choriocarcinoma arose from the PM, DNA from the PM and c
29 enium 2, in the cubilin expressing placental choriocarcinoma BeWo cell line.
30  by which BCRP expression in human placental choriocarcinoma BeWo cells is regulated by progesterone.
31                 We demonstrate that in human choriocarcinoma BeWo cells, the PKC activator 12-O-tetra
32 hat TEF-1 represses hCS promoter activity in choriocarcinoma (BeWo) cells, suggesting that TEF-1 inte
33 omic organization of the IGF2-H19 locus in a choriocarcinoma cancer cell line (JEG3).
34 (EC), teratoma (T), yolk sac tumor (YS), and choriocarcinoma (CC) on the basis of the lineage differe
35  have isolated a cDNA from a human placental choriocarcinoma cell cDNA library which, when expressed
36                       We used an established choriocarcinoma cell line (BeWo cells) that can be induc
37 enate, biotin, and lipoate, from a placental choriocarcinoma cell line (JAR).
38 ected alpha subunit reporter gene in a human choriocarcinoma cell line (JEG3).
39 ic cells, whereas it is not expressed in the choriocarcinoma cell line BeWo.
40 59)Fe-hTF into BeWo cells, a human placental choriocarcinoma cell line in culture.
41 on using antisense technology, using the rat choriocarcinoma cell line Rcho-1 as a trophoblastic cell
42 lysis of ELF3-deficient JEG-3 cells, a human choriocarcinoma cell line widely used to study EVT biolo
43 nsient transfection assays in JEG-3 cells, a choriocarcinoma cell line with negligible endogenous NFI
44 that have either moderate (BeWo, a placental choriocarcinoma cell line) or high (MCF-7/MX100, a breas
45 st differentiation and fusion using the BeWo choriocarcinoma cell line, a model of villous cytotropho
46 jects increases annexin V levels on the BeWo choriocarcinoma cell line, consistent with mobilization
47 ation to endoreduplication in the Rcho-1 rat choriocarcinoma cell line.
48  as well as in BeWo cells, a human placental choriocarcinoma cell line.
49 atan sulfate expressed by JAR cells, a human choriocarcinoma cell line.
50 ype-specific, with greatest activity seen in choriocarcinoma cell lines (4-10-fold enhancement).
51 ream enhancer functions in the JEG-3 and JAR choriocarcinoma cell lines but not in adipocytes or HeLa
52        Furthermore, only trophoblast-derived choriocarcinoma cell lines expressed HERV-PTN mRNA where
53 viously reported the identification of human choriocarcinoma cell lines that have very high levels of
54 on analysis in human (BeWo) and rat (Rcho-1) choriocarcinoma cell lines to examine trophoblast cell-s
55  term placentas, purified trophoblast cells, choriocarcinoma cell lines, and human umbilical vein end
56  profiles of transactivation between the two choriocarcinoma cell lines, but maximal activation in bo
57    When DOC-2/hDab2 was transfected into the choriocarcinoma cell lines, Jar, JEG and BeWo, the stabl
58 acentas, term cytotrophoblast cells, and two choriocarcinoma cell lines, JEG-3 and Jar.
59  normal trophoblast cells in culture than in choriocarcinoma cell lines.
60 l pregnancy and that secreted by three human choriocarcinoma cell lines.
61 al analysis in transiently transfected human choriocarcinoma cells (BeWo).
62 ter and Na+ and K+ contents were measured in choriocarcinoma cells (JAr cell line; 96% of which are u
63 riptional regulator that binds to the JRE in choriocarcinoma cells (JEG3 cells).
64                                              Choriocarcinoma cells and HeLa cells express comparable
65  interaction between Dlx3 and Smad6 in human choriocarcinoma cells and in differentiated trophoblasts
66  from embryonal carcinoma cells, but also in choriocarcinoma cells and in MCF-7 breast carcinoma cell
67 n, the PLE3 element was a strong enhancer in choriocarcinoma cells but not in HeLa cells.
68  the activity of a promoter test fragment in choriocarcinoma cells by 80%.
69                             Finally, the JAR choriocarcinoma cells elaborated EPO into the culture me
70 icantly reduced in human trophoblast-derived choriocarcinoma cells relative to HeLa epithelial or fib
71  of one hypothesis in human placenta-derived choriocarcinoma cells reveal that knockdown of mediator
72 66 element is shown to be activated in JEG-3 choriocarcinoma cells through synergistic interactions b
73 ophoblastic neoplasias, and is essential for choriocarcinoma cells to survive and escape from apoptos
74                               JEG-3 and BeWo choriocarcinoma cells treated with ET-1 displayed an inc
75                                        MTX-R choriocarcinoma cells undergo cell cycle delay in G1 pha
76 osphoproteome of MTX-resistant and sensitive choriocarcinoma cells using quantitative mass-spectromet
77 behavior of CLIC-5A in vivo, JEG-3 placental choriocarcinoma cells were stably transfected with epito
78  nuclear membranes isolated from JEG-3 human choriocarcinoma cells with epidermal growth factor (EGF)
79                                        Human choriocarcinoma cells with high endogenous BCRP expressi
80                                 Treatment of choriocarcinoma cells with the tyrosine phosphatase inhi
81 ass I molecules is abrogated in HSV-infected choriocarcinoma cells, a phenomenon mediated by the vira
82 ed by 27-OHC in COS-1 cells, Y-1 cells, BeWo choriocarcinoma cells, Chinese hamster ovary (CHO) cells
83 The StAR gene promoter is not active in BeWo choriocarcinoma cells, COS-1 cells, HeLa cells, or SK-OV
84 addition, cultured JAR (trophoblast-derived) choriocarcinoma cells, cytotrophoblasts isolated from te
85 hoblast stem cells, organoids, primary EVTs, choriocarcinoma cells, or villous explant cultures unrav
86 llel in primary mouse trophoblasts and human choriocarcinoma cells, we modeled HIF-1 induction and de
87 in is drastically up-regulated by hypoxia in choriocarcinoma cells, whereas expression of PIGF is not
88  by the overexpression of Ets-2 in human JAr choriocarcinoma cells, which are permissive for IFNT exp
89 oblasts isolated from term placenta, and JAR choriocarcinoma cells.
90  in vitro but has no effect on that of human choriocarcinoma cells.
91 wn to direct optimal GCAP gene expression in choriocarcinoma cells.
92 he hCGbeta subunit (hCGbeta) promoter in JAr choriocarcinoma cells.
93 sts and NIH 3T3 cells but totally lacking on choriocarcinoma cells.
94 , on cellular proliferation and apoptosis in choriocarcinoma cells.
95 GPR30; a similar effect was observed in JEG3 choriocarcinoma cells.
96 of JAK-2 is compromised in IFN-gamma-treated choriocarcinoma cells.
97 ion in syncytializing primary cells and BeWo choriocarcinoma cells.
98 red to placental fibroblasts and human JEG-3 choriocarcinoma cells.
99 ation of this site abolished its activity in choriocarcinoma cells.
100 ssion of growth factor pleiotrophin in human choriocarcinoma cells.
101 via a dynamin-independent mechanism in JEG-3 choriocarcinoma cells.
102 sis of mouse pituitary tumor cells and human choriocarcinoma cells.
103  only a very low level of gene expression in choriocarcinoma cells; the expression does not respond t
104 7 and MDA-MB-231 breast cancer cells and JAR choriocarcinoma cells; we also show for the first time t
105  genetic analysis showed that the subsequent choriocarcinomas contained identical single maternal and
106                                            A choriocarcinoma-derived cell line (JAr) which, unlike th
107  are often a mixture of teratoma and cancer (choriocarcinoma, embryonal carcinoma, seminoma, and/or y
108 tly requires treatment with chemotherapy, to choriocarcinoma, for which multi-agent chemotherapy is t
109 d mouse trophoblast cell lines akin to human choriocarcinomas form tumors in syngeneic and immunodefi
110 he depletion of HERV-PTN mRNA prevents human choriocarcinoma growth, invasion, and angiogenesis in mi
111 insurance, higher income, ovarian cancer and choriocarcinoma had better FT.
112 own previously that PDGF-A overexpression in choriocarcinoma, hepatoma and lung carcinoma cell lines
113 , women with ovarian and uterine cancers and choriocarcinoma, higher disease stages, and worse ECOG s
114 s ratio [OR] 1.9 [95% CI 1.1-3.2], p=0.018), choriocarcinoma histology (3.7 [1.9-7.4], p=0.0002), and
115              In patient subgroups defined by choriocarcinoma histology and metastatic disease status,
116 inoma arose from the PM, DNA from the PM and choriocarcinoma in each patient was compared using micro
117                       This was identified as choriocarcinoma in three cases.
118 estational trophoblastic neoplasia including choriocarcinoma is often effectively treated with Methot
119 HO and Lec4 cells) and endogenous (placental choriocarcinoma JAR cells) expression systems, we tested
120                              Human placental choriocarcinoma (JAR) cells endogenously expressing glyc
121 nd a stringent RNA pulldown assay with human choriocarcinoma (JAR) cells, we demonstrate that the sfR
122                           In human placental choriocarcinoma (JAR) cells, which have been previously
123  phosphorylation and ubiquitination in human choriocarcinoma JEG-3 and mouse pituitary AtT20 cells.
124 otile and invasive in culture as compared to choriocarcinoma JEG-3 cells and normal extravillous trop
125 bal transcriptional effect of PTTG1 in human choriocarcinoma JEG-3 cells by simultaneously assessing
126 g activity when transiently transfected into choriocarcinoma JEG-3 cells in contrast to HeLa cells.
127                                  Using human choriocarcinoma JEG-3 cells, we found that sustained act
128 no-terminal p300/CBP binding domain in human choriocarcinoma JEG-3 cells.
129 vitro, but neither placental fibroblasts nor choriocarcinoma (malignant trophoblast) cell lines did s
130 se results reveal a route by which malignant choriocarcinoma may arise from molar pregnancies.
131                                 In a case of choriocarcinoma MCM8 mRNA is aberrant, leading to expres
132 gated the significance of HERV-PTN mRNA in a choriocarcinoma model by targeting this transcript with
133 cinoma (n = 1), yolk sac tumor (n = 107), or choriocarcinoma (n = 1).
134                                          All choriocarcinomas (n = 33), 90% of epithelioid trophoblas
135 on blocks or markedly reduces the binding of choriocarcinoma nuclear factors to the PLAP promoter, le
136 men were diagnosed of having postgestational choriocarcinoma on the basis of persistently positive hu
137 n HepG2 hepatoma cells, but inactive in JEG3 choriocarcinoma or 3T3 cells.
138                          BeWo cells, a human choriocarcinoma placental cell line, behaved as did Menk
139                    This group is composed of choriocarcinoma, placental-site trophoblastic tumour, an
140  mouse embryo ectoplacental cone and the rat choriocarcinoma (Rcho-1) cell line, that trophoblast dif
141 iven to patients with metastatic disease and choriocarcinoma, regardless of pretreatment human chorio
142 protocols for the diagnosis and treatment of choriocarcinoma should be modified to include a compulso
143 Loss-of-function using plgf shRNA in a human choriocarcinoma significantly accelerated tumor growth r
144 novel therapeutic strategies to tackle MTX-R choriocarcinoma that could rapidly be translated into th
145 lateral non-gestational pure primary ovarian choriocarcinoma that was confirmed by beta human chorion
146 ver previously been proven to transform into choriocarcinoma, the most malignant form of gestational
147                                   Except for choriocarcinoma, the neoplasms that develop from human t
148 ibits Wilms, rhabdoid, rhabdomyosarcoma, and choriocarcinoma tumor cell growth, and silencing HOTS by
149 o in hormone-sensitive breast, prostate, and choriocarcinoma tumors to slow their growth.
150 lateral non-gestational pure primary ovarian choriocarcinoma was made.
151  patient nearly died before the diagnosis of choriocarcinoma was made.
152         The histology of both PM and ensuing choriocarcinoma was reviewed and flow cytometry used to
153 atients with a PM who developed a subsequent choriocarcinoma were identified from our GTD database.
154   Viable tumor included embryonal carcinoma, choriocarcinoma, yolk sac carcinoma, seminoma, and terat

 
Page Top